RxDoctor Payments Data

Amar Shah, MD

Ophthalmology · Miami, FLNPI 1457715237

Payments from drug & device makers

$93,201in general payments, 2019–2025

Across 323 payments — averaging $288.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$59K
  • Sun Pharmaceutical Industries Inc.$15K
  • Tarsus Pharmaceuticals, Inc.$7K
  • Biotissue Holdings Inc.$4K
  • Oyster Point Pharma, Inc.$3K
  • Alcon$1K
  • plus $4K from 20 others

What the payments were for

  • Consulting fees$9,85011%
  • Speaking & faculty fees$63,34070%
  • Travel & lodging$5,2896%
  • Food & beverage$12,20313%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$93,201 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$239,171
Medicare patients
426
Services billed
1,741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OxervateCenegermin-Bkbj18$617,302
RestasisCyclosporine156$172,643
XiidraLifitegrast140$168,960
CequaCyclosporine82$56,614
MieboPerfluorohexyloctane/Pf74$54,553
XdemvyLotilaner25$46,262
Cyclosporine49$40,895
Prednisolone Acetate511$19,934
VevyeCyclosporine16$14,888
MoxifloxacinMoxifloxacin Hcl397$11,247
TyrvayaVarenicline Tartrate13$8,147
FlarexFluorometholone Acetate48$5,888
Loteprednol Etabonate49$5,052
Bromfenac Sodium26$4,318
Ketorolac Tromethamine194$3,404

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Dompe US, Inc.Oxervate$127$617,30218 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo$59,495$223,513214 claims
AbbVieRestasis$254$172,643156 claims
Sun Pharmaceutical Industries Inc.Cequa, Bromsite$14,546$59,72294 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$7,251$46,26225 claims
Harrow Eye, LLCVevye$75$14,88816 claims
Oyster Point Pharma, Inc.Tyrvaya$2,920$8,14713 claims
Eyevance Pharmaceuticals LLCFlarex$40$5,88848 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$35$5,05249 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →